Neuronal inclusions of α-synuclein contribute to the pathogenesis of Krabbe disease

Journal of Pathology

Volumn 232, Issue 5, 2014, Pages 509-521

  Smith, Benjamin R ^a   Santos, Marta B ^a   Marshall, Michael S ^a   Cantuti Castelvetri, Ludovico ^a   Lopez Rosas, Aurora ^a   Li, Guannan ^b   Van Breemen, Richard ^b   Claycomb, Kumiko I ^c   Gallea, Jose I ^d   Celej, Maria S ^d   Crocker, Stephen J ^c   Givogri, Maria I ^a   Bongarzone, Ernesto R ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^d UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

Author keywords

axonal degeneration; dying back pathology; Krabbe disease; Lewy bodies; myelin; psychosine; synucleinopathies; ubiquitin; synuclein

Indexed keywords

ALPHA SYNUCLEIN; PSYCHOSINE; UBIQUITIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BETA SHEET; BRAIN CORTEX; CELL AGGREGATION; CELL INCLUSION; CEREBELLUM; COGNITION; CONTROLLED STUDY; CYTOPLASM; ELECTRON MICROSCOPY; FRONTAL CORTEX; GLOBOID CELL LEUKODYSTROPHY; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; HYPOTHALAMUS; IMMUNOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFERIOR COLLICULUS; LEWY BODY; LIQUID CHROMATOGRAPHY; MESENCEPHALON; MICROGLIA; MOTOR PERFORMANCE; MOUSE; NERVE CELL; NEUROLOGIC DISEASE; NONHUMAN; NUCLEUS ACCUMBENS; OLFACTORY BULB; OLIGODENDROGLIA; PARKINSON DISEASE; PATHOGENESIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PUTAMEN; REAL TIME POLYMERASE CHAIN REACTION; STEREOLOGY; SUBSTANTIA NIGRA; TANDEM MASS SPECTROMETRY; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

AXONAL DEGENERATION; DYING-BACK PATHOLOGY; KRABBE DISEASE; LEWY BODIES; MYELIN; PSYCHOSINE; SYNUCLEINOPATHIES; UBIQUITIN; Α-SYNUCLEIN;

ALPHA-SYNUCLEIN; ANIMALS; BRAIN; CASE-CONTROL STUDIES; COGNITION; DISEASE MODELS, ANIMAL; FLUORESCENT DYES; HUMANS; LEUKODYSTROPHY, GLOBOID CELL; LEWY BODIES; MICE; MOTOR ACTIVITY; MUTATION; NEURONS; PSYCHOSINE; THIAZOLES;

EID: 84895927010     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4328     Document Type: Article

References (89)

1. Suzuki K, Iseki E, Togo T, et al., Neuronal and glial accumulation of alpha- and beta-synucleins in human lipidoses. Acta Neuropathol 2007; 114: 481-489.
2. Wenger DA, Rafi MA, Luzi P,. Molecular genetics of Krabbe disease (globoid cell leukodystrophy): diagnostic and clinical implications. Hum Mutat 1997; 10: 268-279.
3. Igisu H, Suzuki K,. Progressive accumulation of toxic metabolite in a genetic leukodystrophy. Science 1984; 224: 753-755.
4. White AB, Givogri MI, Lopez-Rosas A, et al., Psychosine accumulates in membrane microdomains in the brain of Krabbe patients, disrupting the raft architecture. J Neurosci 2009; 29: 6068-6077.
5. Suzuki K., Twenty five years of the 'psychosine hypothesis': a personal perspective of its history and present status. Neurochem Res 1998; 23: 251-259.
6. Suzuki K, Suzuki Y,. Krabbe's globoid cell leukodystrophy: deficiency of galactocerebroside beta-galactosidase activity. J Neuropathol Exp Neurol 1971; 30: 145.
7. Komiyama A, Suzuki K,. Progressive impairment of Schwann cell proliferation in vitro in murine globoid cell leukodystrophy (twitcher). Brain Res 1992; 598: 1-9.
8. Nagara H, Ogawa H, Sato Y, et al., The twitcher mouse: degeneration of oligodendrocytes in vitro. Brain Res 1986; 391: 79-84.
9. Suzuki K, Suzuki K,. Myelin pathology in the twitcher mouse. Ann N Y Acad Sci 1990; 605: 313-324.
10. Tohyama J, Matsuda J, Suzuki K,. Psychosine is as potent an inducer of cell death as C6-ceramide in cultured fibroblasts and in MOCH-1 cells. Neurochem Res 2001; 26: 667-671.
11. Giri S, Jatana M, Rattan R, et al., Galactosylsphingosine (psychosine)-induced expression of cytokine-mediated inducible nitric oxide synthases via AP-1 and C/EBP: implications for Krabbe disease. FASEB J 2002; 16: 661-672.
12. Giri S, Khan M, Nath N, et al., The role of AMPK in psychosine mediated effects on oligodendrocytes and astrocytes: implication for Krabbe disease. J Neurochem 2008; 105: 1820-1833.
13. Giri S, Khan M, Rattan R, et al., Krabbe disease: psychosine-mediated activation of phospholipase A2 in oligodendrocyte cell death. J Lipid Res 2006; 47: 1478-1492.
14. Haq E, Giri S, Singh I, et al., Molecular mechanism of psychosine-induced cell death in human oligodendrocyte cell line. J Neurochem 2003; 86: 1428-1440.
15. Cantuti Castelvetri L, Givogri MI, Hebert A, et al., The sphingolipid psychosine inhibits fast axonal transport in Krabbe disease by activation of GSK3beta and deregulation of molecular motors. J Neurosci 2013; 33: 10048-10056.
16. Cantuti-Castelvetri L, Zhu H, Givogri MI, et al., Psychosine induces the dephosphorylation of neurofilaments by deregulation of PP1 and PP2A phosphatases. Neurobiol Dis 2012; 46: 325-335.
17. Castelvetri LC, Givogri MI, Zhu H, et al., Axonopathy is a compounding factor in the pathogenesis of Krabbe disease. Acta Neuropathol 2011; 122: 35-48.
18. Dunn HG, Lake BD, Dolman CL, et al., The neuropathy of Krabbe's infantile cerebral sclerosis: globoid cell leucodystrophy. Brain 1969; 92: 329-344.
19. Kurtz HJ, Fletcher TF,. The peripheral neuropathy of canine globoid-cell leukodystrophy (Krabbe-type). Acta Neuropathol 1970; 16: 226-232.
20. Krabbe K., A new familial, infantile form of diffuse brain sclerosis. Brain 1916; 39: 74-114.
21. Smith B, Galbiati F, Castelvetri LC, et al., Peripheral neuropathy in the Twitcher mouse involves the activation of axonal caspase 3. ASN Neuro 2011; 3: 213-222.
22. Duchen LW, Eicher EM, Jacobs JM, et al., Hereditary leucodystrophy in the mouse: the new mutant twitcher. Brain 1980; 103: 695-710.
23. Sakai N, Inui K, Tatsumi N, et al., Molecular cloning and expression of cDNA for murine galactocerebrosidase and mutation analysis of the twitcher mouse, a model of Krabbe's disease. J Neurochem 1996; 66: 1118-1124.
24. Kobayashi T, Yamanaka T, Jacobs JM, et al., The twitcher mouse: an enzymatically authentic model of human globoid cell leukodystrophy (Krabbe disease). Brain Res 1980; 202: 479-483.
25. Jakes R, Spillantini MG, Goedert M,. Identification of two distinct synucleins from human brain. FEBS Lett 1994; 345: 27-32.
26. Withers GS, George JM, Banker GA, et al., Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons. Brain Res Dev Brain Res 1997; 99: 87-94.
27. Byrne EJ, Lennox G, Lowe J, et al., Diffuse Lewy body disease: clinical features in 15 cases. J Neurol Neurosurg Psychiatry 1989; 52: 709-717.
28. Hurtig HI, Trojanowski JQ, Galvin J, et al., Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000; 54: 1916-1921.
29. Lennox G, Lowe J, Byrne EJ, et al., Diffuse Lewy body disease. Lancet 1989; 1: 323-324.
30. Lennox G, Lowe J, Landon M, et al., Diffuse Lewy body disease: correlative neuropathology using anti-ubiquitin immunocytochemistry. J Neurol Neurosurg Psychiatry 1989; 52: 1236-1247.
31. Lippa CF, Fujiwara H, Mann DM, et al., Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 1998; 153: 1365-1370.
32. Spillantini MG, Schmidt ML, Lee VM, et al., Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839-840.
33. Hashimoto M, Hsu LJ, Sisk A, et al., Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. Brain Res 1998; 799: 301-306.
34. Biere AL, Wood SJ, Wypych J, et al., Parkinson's disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs. J Biol Chem 2000; 275: 34574-34579.
35. Kessler JC, Rochet JC, Lansbury PT Jr., The N-terminal repeat domain of alpha-synuclein inhibits beta-sheet and amyloid fibril formation. Biochemistry 2003; 42: 672-678.
36. Conway KA, Lee SJ, Rochet JC, et al., Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A 2000; 97: 571-576.
37. Goldberg MS, Lansbury PT Jr., Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nature Cell Biol 2000; 2: E115-E119.
38. Cabin DE, Shimazu K, Murphy D, et al., Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci 2002; 22: 8797-8807.
39. Gadad BS, Britton GB, Rao KS,. Targeting oligomers in neurodegenerative disorders: lessons from alpha-synuclein, tau, and amyloid-beta peptide. J Alzheimers Dis 2011; 24 (Suppl 2): 223-232.
40. Waxman EA, Giasson BI,. Molecular mechanisms of alpha-synuclein neurodegeneration. Biochim Biophys Acta 2009; 1792: 616-624.
41. Giasson BI, Murray IV, Trojanowski JQ, et al., A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem 2001; 276: 2380-2386.
42. Giasson BI, Uryu K, Trojanowski JQ, et al., Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem 1999; 274: 7619-7622.
43. Miake H, Mizusawa H, Iwatsubo T, et al., Biochemical characterization of the core structure of alpha-synuclein filaments. J Biol Chem 2002; 277: 19213-19219.
44. Murray IV, Giasson BI, Quinn SM, et al., Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry 2003; 42: 8530-8540.
45. Narhi L, Wood SJ, Steavenson S, et al., Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J Biol Chem 1999; 274: 9843-9846.
46. Serpell LC, Berriman J, Jakes R, et al., Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci U S A 2000; 97: 4897-4902.
47. Wood SJ, Wypych J, Steavenson S, et al., α-Synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J Biol Chem 1999; 274: 19509-19512.
48. Galbiati F, Basso V, Cantuti L, et al., Autonomic denervation of lymphoid organs leads to epigenetic immune atrophy in a mouse model of Krabbe disease. J Neurosci 2007; 27: 13730-13738.
49. Youmans KL, Tai LM, Nwabuisi-Heath E, et al., APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of Alzheimer disease. J Biol Chem 2012; 287: 41774-41786.
50. Sharon R, Bar-Joseph I, Frosch MP, et al., The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 2003; 37: 583-595.
51. Cleary JP, Walsh DM, Hofmeister JJ, et al., Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nature Neurosci 2005; 8: 79-84.
52. Barnes JH,. The physiology and pharmacology of emesis. Mol Aspects Med 1984; 7: 397-508.
53. Noronha LD, Sampaio G, Bruck I, et al., [ Krabbe's disease-case report ]. J Pediatr (Rio J) 2000; 76: 79-82 (in Portuguese).
54. Jean A., Brain stem control of swallowing: neuronal network and cellular mechanisms. Physiol Rev 2001; 81: 929-969.
55. Hornby PJ,. Central neurocircuitry associated with emesis. Am J Med 2001; 111 (Suppl 8A): 106S-112S.
56. Hagberg B., Krabbe's disease: clinical presentation of neurological variants. Neuropediatrics 1984; 15 (Suppl): 11-15.
57. Crome L, Hanefeld F, Patrick D, et al., Late onset globoid cell leucodystrophy. Brain 1973; 96: 841-848.
58. Altman J, Carpenter MB,. Fiber projections of the superior colliculus in the cat. J Comp Neurol 1961; 116: 157-177.
59. Trachtman JN,. Vision and the hypothalamus. Optometry 2010; 81: 100-115.
60. Harrington ME,. The ventral lateral geniculate nucleus and the intergeniculate leaflet: interrelated structures in the visual and circadian systems. Neurosci Biobehav Rev 1997; 21: 705-727.
61. Mori F, Piao YS, Hayashi S, et al., Alpha-synuclein accumulates in Purkinje cells in Lewy body disease but not in multiple system atrophy. J Neuropathol Exp Neurol 2003; 62: 812-819.
62. Lotharius J, Brundin P,. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nature Rev Neurosci 2002; 3: 932-942.
63. Al-Essa MA, Bakheet SM, Patay ZJ, et al., Clinical and cerebral FDG PET scan in a patient with Krabbe's disease. Pediatric Neurol 2000; 22: 44-47.
64. Rub U, Del Tredici K, Schultz C, et al., Parkinson's disease: the thalamic components of the limbic loop are severely impaired by alpha-synuclein immunopositive inclusion body pathology. Neurobiol Aging 2002; 23: 245-254.
65. Kobayashi O, Takashima S,. Thalamic hyperdensity on CT in infantile GM1-gangliosidosis. Brain Dev 1994; 16: 472-474.
66. Stalker HP, Han BK,. Thalamic hyperdensity: a previously unreported sign of Sandhoff disease. AJNR Am J Neuroradiol 1989; 10: S82.
67. Jardim LB, Giugliani R, Fensom AH,. Thalamic and basal ganglia hyperdensities-a CT marker for globoid cell leukodystrophy? Neuropediatrics 1992; 23: 30-31.
68. Kwan E, Drace J, Enzmann D,. Specific CT findings in Krabbe disease. AJR Am J Roentgenol 1984; 143: 665-670.
69. Eidelberg D, Takikawa S, Moeller JR, et al., Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease. Ann Neurol 1993; 33: 518-527.
70. Lundvig D, Lindersson E, Jensen PH,. Pathogenic effects of alpha-synuclein aggregation. Brain Res Mol Brain Res 2005; 134: 3-17.
71. Harper JD, Lansbury PT Jr., Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem 1997; 66: 385-407.
72. Volles MJ, Lee SJ, Rochet JC, et al., Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 2001; 40: 7812-7819.
73. Conway KA, Harper JD, Lansbury PT,. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nature Med 1998; 4: 1318-1320.
74. Dickson DW, Liu W, Hardy J, et al., Widespread alterations of alpha-synuclein in multiple system atrophy. Am J Pathol 1999; 155: 1241-1251.
75. Kahle PJ, Neumann M, Ozmen L, et al., Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol 2001; 159: 2215-2225.
76. Winner B, Jappelli R, Maji SK, et al., In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A 2011; 108: 4194-4199.
77. Pountney DL, Voelcker NH, Gai WP,. Annular alpha-synuclein oligomers are potentially toxic agents in alpha-synucleinopathy. Hypothesis. Neurotox Res 2005; 7: 59-67.
78. Rochet JC, Conway KA, Lansbury PT Jr., Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. Biochemistry 2000; 39: 10619-10626.
79. Conway KA, Lee SJ, Rochet JC, et al., Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants. Ann N Y Acad Sci 2000; 920: 42-45.
80. Eliezer D, Kutluay E, Bussell R Jr, et al., Conformational properties of alpha-synuclein in its free and lipid-associated states. J Mol Biol 2001; 307: 1061-1073.
81. Jo E, McLaurin J, Yip CM, et al., α-Synuclein membrane interactions and lipid specificity. J Biol Chem 2000; 275: 34328-34334.
82. Ding TT, Lee SJ, Rochet JC, et al., Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry 2002; 41: 10209-10217.
83. Sharon R, Goldberg MS, Bar-Josef I, et al., α-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc Natl Acad Sci U S A 2001; 98: 9110-9115.
84. Narayanan V, Scarlata S,. Membrane binding and self-association of alpha-synucleins. Biochemistry 2001; 40: 9927-9934.
85. Zhu M, Fink AL,. Lipid binding inhibits alpha-synuclein fibril formation. J Biol Chem 2003; 278: 16873-16877.
86. Fortin DL, Troyer MD, Nakamura K, et al., Lipid rafts mediate the synaptic localization of alpha-synuclein. J Neurosci 2004; 24: 6715-6723.
87. Ahmed Z, Asi YT, Sailer A, et al., The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol Appl Neurobiol 2012; 38: 4-24.
88. Matsuo A, Akiguchi I, Lee GC, et al., Myelin degeneration in multiple system atrophy detected by unique antibodies. Am J Pathol 1998; 153: 735-744.
89. Wakabayashi K, Takahashi H,. Cellular pathology in multiple system atrophy. Neuropathology 2006; 26: 338-345.